[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"tmj-pain\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:tmj-pain":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,42,77,101,138,163],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100637183","a-double-blind-placebo-controlled-evaluation-of-the-effect-of-the-erchonia-evrl-on-chronic-jaw-pain-arising-from-tmj-100637183",false,"NCT07600203","A Double-blind, Placebo-controlled Evaluation of the Effect of the Erchonia® EVRL on Chronic Jaw Pain Arising From TMJ","A Double-blind, Placebo-controlled, Randomized Evaluation of the Effect of the Erchonia® EVRL on Chronic Jaw Pain Arising From TMJ Clinical Study Protocol","Inclusion Criteria:\n\n* Able to understand and voluntarily sign the IRB-approved informed consent form.\n* Adults 22 to 75 years of age.\n* Subject's self-reported rating for jaw pain on the 0-100 VAS pain scale is 50 or greater (≥ 50).\n* Constant jaw pain on-going over at least the past 3 months.\n* Subjects score ≥3 points on the validated TMD Pain Screener (long version).\n* Subject has a primary diagnosis of TMJ-related nociceptive musculoskeletal pain made by a suitably qualified healthcare professional, confirmed using the Diagnostic Criteria for Temporomandibular Disorders (DC\u002FTMD) Axis I, with at least one of the following pain-related diagnoses: myalgia (including local myalgia, myofascial pain, myofascial pain with spreading, myofascial pain with referral) and\u002For arthralgia.\n* Subject is willing and able to refrain from consuming any OTC and\u002For prescription medications including muscle relaxants and\u002For herbal supplements and\u002For recreational and medical drugs including cannabis intended for the relief of pain and\u002For inflammation throughout the course of study participation, except for the study-specific pain relief medication of OTC Tylenol.\n* Subject agrees to refrain from taking a dosage of the study rescue pain medication of over-the-counter Regular Strength Tylenol® tablets for at least 6 hours before a scheduled VAS jaw pain rating is to be recorded. The subject understands that he may take a dosage of the over-the-counter Regular Strength Tylenol® tablets right after the VAS rating has been recorded, if needed to manage jaw pain.\n* Subject is willing and able to refrain from engaging in any non-study procedure therapies for the management of his or her jaw pain throughout the course of study participation, including conventional therapies such as physical therapy, occupational therapy and hot or cold packs, as well as alternative therapies such as chiropractic care and acupuncture\n* Subject is able to communicate fluently in English with the investigator and is able to read and write English sufficiently to comply with the study procedures.\n\nExclusion Criteria:\n\n* Pain that is undiagnosed or determined by a qualified medical\u002Fdental professional to be primarily attributable to causes other than TMJ-related nociceptive musculoskeletal pain.\n* Diagnosis using the Diagnostic Criteria for Temporomandibular Disorders (DC\u002FTMD) Axis I does not include at least one of the following pain-related diagnoses: myalgia (including local myalgia, myofascial pain, myofascial pain with spreading, myofascial pain with referral) and\u002For arthralgia OR includes one or more of the following pain-related diagnoses: disc displacement disorder with reduction, disc replacement disorder with reduction with intermittent locking, disc displacement disorder without reduction with limited opening, disc displacement disorder without reduction without limited opening, degenerative joint disease, headache attributed to RMD, and subluxation.\n* History of surgical intervention involving the temporomandibular joint within the past 12 months, or any history of total joint replacement or major reconstructive surgery of the TMJ.\n* Intra-articular TMJ interventions, including corticosteroid injections, botulinum toxin injections, or prolotherapy, within 3 months prior to enrollment.\n* Neurologic, neuromuscular, or neuropathic conditions affecting the craniofacial region that could confound TMJ pain assessment, including:\n\n  1. Diagnosed conditions: trigeminal neuralgia, Parkinson's disease, or other neuropathic facial pain disorders\n  2. Pain primarily characterized by neuropathic descriptors (burning, shooting, electric-like, sharp\u002Fstabbing pain, paresthesias, numbness, or tingling).\n* TMJ ankylosis or severe structural deformity requiring surgical intervention.\n* Degenerative disc disease or internal derangement of the temporomandibular joint associated with significant structural degeneration, disc perforation, or requiring surgical intervention.\n* Diagnosed systemic inflammatory or autoimmune conditions that could confound pain assessment (e.g., active rheumatoid arthritis, lupus) unless stable and well controlled.\n* Active cancer or treatment for cancer in the past 6 months.\n* Active infection, wound, or other external trauma to the areas to be treated with the laser.\n* Medical, physical, or other contraindications for, or sensitivity to, light therapy.\n* Pregnant, breast feeding, or planning pregnancy prior to the end of study participation.\n* Serious mental health illness such as dementia or schizophrenia; psychiatric hospitalization in past two years.\n* Developmental disability or cognitive impairment that in the opinion of the investigator would preclude adequate comprehension of the informed consent form and\u002For ability to record the necessary study measurements.\n* Any condition or other variable that in the opinion of the investigator may confound or interfere with the evaluation of the effectiveness of the investigational treatment or otherwise render the subject unable to comply with the requirements of the study protocol.","ALL","22 Years","75 Years",{"count":20,"type":21},64,"ESTIMATED","INTERVENTIONAL",[24],"NA","The purpose of this clinical study is to determine the effectiveness of the Erchonia EVRL, manufactured by Erchonia Corporation (the Company), in providing temporary relief of nociceptive musculoskeletal chronic jaw pain arising from temporomandibular joint (TMJ).",[27,28,29],"TMJ","TMJ Pain","TMD","RECRUITING","2026-05-14",{"date":33,"type":34},"2026-05-20","ACTUAL",{"date":31,"type":34},{"date":37,"type":21},"2027-12-22",{"name":39,"class":40},"Erchonia Corporation","INDUSTRY",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":49,"maxAge":18,"enrollmentInfo":50,"targetDuration":4,"studyType":22,"phases":52,"briefSummary":54,"conditions":55,"keywords":59,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":41},"100634185","phase-3-biologic-augmentation-of-tmj-arthroscopy-using-bmac-100634185","NCT07536399","Biologic Augmentation of TMJ Arthroscopy Using BMAC","Biologic Augmentation of Temporomandibular Joint Arthroscopy Using Bone Marrow Aspirate Concentrate (BMAC): A Proposed Clinical Trial","Inclusion Criteria:\n\n1. Participant is at least 18 years of age and not older than 75 years of age\n2. Participant is willing and able to provide written informed consent to participant in this study\n3. Participant has symptoms of TMJ arthralgia (pain) with significant temporomandibular joint pain and dysfunction despite at least 30 days of conservative therapy (NSAIDS, muscle relaxants, bite splints, PT, warm compresses, soft diet, etc.)\n4. Participant has baseline pain of ≥30 on a 100mm visual analog scale (VAS)\n\nExclusion Criteria:\n\n1. Participant has not competed at least 30 days of conservative therapy\n2. Participant was diagnosed with central or neuropathic pain disorder\n3. Participant has a primary diagnosis of myofascial pain\n4. Participant has fibromyalgia\n5. Participant is pregnant or breastfeeding\n6. Participant had traumatic injury to the masticatory muscles or temporomandibular joint within 12 months of screening\n7. Participant who has the following contraindications to MRI:\n\n   * Electrical implants such as cardiac pacemakers or perfusion pumps\n   * Ferromagnetic implants such as aneurysm clips, surgical clips, prostheses, artificial heart, valves with steel parts, metal fragments, shrapnel, bullets, tattoos near the eye, or steel implants\n   * History of seizures\n   * Patients with GFR \\\u003C 15 ml\u002Fmin\u002F1.73m2 or who are on dialysis will be excluded from the study.\n   * Allergy to contrast die","18 Years",{"count":51,"type":21},20,[53],"PHASE3","The goal of this clinical trial is to learn about the efficacy of using Bone Marrow Aspirate Concentrate (BMAC) during temporomandibular joint (TMJ) arthroscopy compared to standard arthroscopic procedures with corticosteroid (CS) injections in patients with pain (arthralgia) of the temporomandibular joint (TMJ) that has failed to respond to conservative treatment. The main question it aims to answer:\n\nDoes BMAC injection reduce the amount of inflammation and structural damage in the TMJ? Researchers will compare BMAC injection to corticosteroid injections see if BMAC injection helps .\n\nParticipants will :\n\n* Be randomized to receive either BMAC or CS injection during TMJ arthroscopy\n* Visit the clinic for 3 follow up visits over 6 months and answer questionnaires\n* have 2 MRIs of their jaw",[56,57,28,58],"TMJ - Oral &Maxillofacial Surgery","Oral and Maxillofacial Conditions","TMJ Arthralgia",[60,61,62,63,64,65],"TMJ pain","Oral and maxillofacial conditions","TMJ arthroscopy","bone marrow aspirate concentrate","BMAC","steroid","NOT_YET_RECRUITING","2026-04-10",{"date":69,"type":34},"2026-04-17",{"date":71,"type":21},"2026-04",{"date":73,"type":21},"2028-06",{"name":75,"class":76},"Weill Medical College of Cornell University","OTHER",{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":4,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":16,"minAge":49,"maxAge":4,"enrollmentInfo":84,"targetDuration":4,"studyType":22,"phases":86,"briefSummary":88,"conditions":89,"keywords":90,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":4},"100627173","phase-2-efficacy-of-triamcinolone-lidocaine-mix-in-trigger-points-injection-of-masseter-muscle-double-blinded-randomized-controlled-trial-100627173","NCT07445191","Efficacy of Triamcinolone-Lidocaine Mix in Trigger Points Injection of Masseter Muscle: Double-blinded, Randomized Controlled Trial","Clinical Assessment of The Efficacy of Triamcinolone-Lidocaine Mix in Trigger Points Injection of Masseter Muscle: Double-blinded, Randomized Controlled Trial","Inclusion criteria\n\n1. Age more than or equal 18 years\n2. Both sexes\n3. Patients' willingness to follow instructions\n\nExclusion criteria\n\n1. Patients who will be using any medications to reduce the pain and\u002For have any effect on the skeletal muscle\n2. Clinical conditions such as pregnancy\n3. Medical problems that may interfere with the procedures such as bleeding disorders\n4. Cognitive impairment or exhibited inadequate cooperation\n5. Patients will be receiving physical therapy or wearing occlusal splint in the same period of the research",{"count":85,"type":21},30,[87,53],"PHASE2","This study aims to clinically evaluate the efficacy of trigger points using active drug mix (Triamcinolone with lidocaine) on relief of myofascial pain of jaw muscle.",[28],[91],"masseter muscle","2026-02-28",{"date":94,"type":34},"2026-03-03",{"date":96,"type":21},"2026-03-01",{"date":98,"type":21},"2026-07-01",{"name":100,"class":76},"Cairo University",{"id":102,"slug":103,"hasResults":11,"nctId":104,"briefTitle":105,"officialTitle":106,"acronym":4,"eligibilityCriteria":107,"healthyVolunteers":108,"sex":16,"minAge":49,"maxAge":4,"enrollmentInfo":109,"targetDuration":4,"studyType":22,"phases":111,"briefSummary":112,"conditions":113,"keywords":119,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":129,"lastUpdatePostDateStruct":130,"startDateStruct":132,"completionDateStruct":134,"leadSponsor":136,"locationsCount":41},"100594388","phase-3-art-based-pain-assessment-tool-in-patients-with-temporomandibular-joint-disorders-100594388","NCT07018791","Art-Based Pain Assessment Tool in Patients With Temporomandibular Joint Disorders","Assessment of the Impact of Art-Based Pain Assessment Tool on Pain Communication, Joint Function, and Anxiety in Patients With Temporomandibular Joint Disorders: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Adults aged 18 years or older\n* Diagnosed with Temporomandibular Disorders (TMD) requiring conservative management only and classified as Wilkes' stage I or II\n* Able to understand and sign the informed consent form\n\nExclusion Criteria:\n\n* Patients requiring surgical intervention for TMD\n* Presence of severe mental illness, such as psychotic disorders or bipolar affective disorders\n* Regular use of narcotic (opioid) pain medications",true,{"count":110,"type":21},70,[53],"Title of Study:\n\nAssessment of the Impact of Art-Based Pain Assessment Tool on Pain Communication, Joint Function, and Anxiety in Patients with Temporomandibular Disorders (TMD): A Randomized Controlled Trial\n\nLocation:\n\nKing Abdulaziz University Dental Hospital (KAUFD), Jeddah, Saudi Arabia What Is This Study About?\n\nThis study examines how an art-based tool can help improve communication and understanding of pain among patients with jaw joint disorders (TMD). It compares two groups:\n\n* Standard care: Routine diagnostic and therapeutic procedures\n* Intervention: Standard care plus a guided art-based tool using paintings to express and discuss the TMD experiences What Is the Art-Based Tool?\n\nThis novel method, called the Artistic Pain Exploration (APE), uses paintings to help patients describe their pain that relates to TMD and its effect on their quality of life:\n\n1. Participants will be shown three paintings (e.g., The Scream by Edvard Munch)\n2. Participants will choose the one that best resonates with them\n3. A guided discussion follows, exploring how the image relates to their physical and emotional pain as well as the effect of pain on their daily activities\n\nResearch Questions:\n\n1. Does using the APE method help participants better communicate and understand their pain?\n2. Does it improve jaw function and reduce anxiety more than standard assessment? Who Can Participate?\n\nParticipants may be eligible if they:\n\n* Are 18 years or older\n* Have early-stage TMD (not needing surgery)\n* Can give informed consent\n\nParticipants cannot participate if they:\n\n* Require jaw surgery\n* Have severe mental illness (e.g., psychosis or bipolar disorder)\n* Take narcotic pain medications regularly What Will Happen During the Study?\n* Participants are randomly assigned to one of the two groups.\n* Each participant will complete a standardized questionnaire before and after two weeks to assess the level of anxiety.\n* All participants will be screened for depression via a standardized questionnaire before the first visit.\n* All will undergo a clinical exam to assess the TMJ pain and function and receive appropriate medications and lifestyle instructions.\n* Some participants (intervention group) will also discuss their pain using the artwork.\n* All participants will be seen for a follow up in 2 weeks to assess the TMJ function and pain.\n\nPotential Risks and Discomforts\n\nParticipants may experience:\n\n* Emotional discomfort while discussing pain\n* Mild anxiety during interviews or questionnaires If needed, a psychiatrist on the research team will provide support or referrals.\n\nPotential Benefits\n\n* A better understanding of pain\n* Improved communication with care provider\n* Possible improvement in pain and jaw function\n\nCosts There are no costs to participate. All treatments are provided free of charge.\n\nCompensation \u002F Treatment for Injury\n\n* If participants experience harm from this study, necessary medical care will be provided by the research team.\n* No financial compensation will be provided by King Abdulaziz University.\n\nConfidentiality Participants' identity and medical records will remain confidential. Only approved researchers and auditors will have access to data, in accordance with applicable laws. Any results published will not include participants' name or identifying details.",[114,115,28,116,117,118],"Temporomandibular Disorders (TMD)","Wilkes 1 and 2","TMJ - Oral &Amp;Maxillofacial Surgery","Art Therapy","TMD Art Pain Study",[120,121,122,123,124,125,126,127,128],"Temporomandibular joint disorders","Artistic Pain Exploration (APE)","Visual Pain Expression","Art-Based Assessment","Multisensory Pain Assessment","Randomized Controlled Trial","Pain Communication","Patient-Reported Outcomes","TMJ Function","2025-06-11",{"date":131,"type":34},"2025-06-15",{"date":133,"type":34},"2025-04-25",{"date":135,"type":21},"2025-10-30",{"name":137,"class":76},"King Abdulaziz University",{"id":139,"slug":140,"hasResults":11,"nctId":141,"briefTitle":142,"officialTitle":143,"acronym":4,"eligibilityCriteria":144,"healthyVolunteers":11,"sex":16,"minAge":49,"maxAge":4,"enrollmentInfo":145,"targetDuration":4,"studyType":147,"phases":4,"briefSummary":148,"conditions":149,"keywords":150,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":154,"lastUpdatePostDateStruct":155,"startDateStruct":157,"completionDateStruct":158,"leadSponsor":160,"locationsCount":41},"100590372","nerve-block-treatment-for-chronic-jaw-pain-100590372","NCT06966557","Nerve Block Treatment for Chronic Jaw Pain","Treatment of Chronic Temporomandibular Pain With Peripheral Nerve Block","Inclusion Criteria:\n\n* Adults (non-pregnant) with sound judgment\n* Chronic TMJ pain lasting at least 12 months\n* Documented failure of at least two previous treatment modalities\n\nExclusion Criteria:\n\n* not meeting inclusion criteria\n* Missing at least two follow-up visits within the specified timeframe",{"count":146,"type":21},40,"OBSERVATIONAL","Study Summary: Nerve Block Treatment for Chronic Jaw Pain This study is being conducted at the TMJ (temporomandibular joint) clinic, which is part of the oral and maxillofacial surgery department. The goal is to evaluate how effective peripheral nerve blocks are in reducing long-term jaw pain in patients with chronic temporomandibular disorders (TMD) who haven't responded to at least two other types of treatment (such as physical therapy, medication, or bite splints).\n\nWhat Is the Treatment? Peripheral nerve blocks are injections that temporarily block nerve signals from the painful area. This can relieve pain and improve function. These blocks are already used routinely at the clinic.\n\nWho Can Join? Adults who have had jaw joint pain for over a year.\n\nHave tried at least two other treatments without success.\n\nAre mentally competent and not pregnant.\n\nWhat Will Participation Involve? You'll receive the nerve block treatment as part of your regular care.\n\nYou'll be asked to attend follow-up visits, typically one every 4 months (3 per year).\n\nYou'll be monitored for pain relief, mouth opening ability, and use of pain medications.\n\nYou can stop participating at any time without affecting your care.\n\nHow Will Data Be Handled? Your information will be stored securely and coded to protect your identity.\n\nOnly the research team will have access to your personal information.\n\nHow Many People Will Be in the Study? The goal is to recruit 40 patients.",[28],[28,151,152,153],"Nerve block","Peripheral nerve block","Chronic temporomandibular pain","2025-06-09",{"date":156,"type":34},"2025-06-10",{"date":133,"type":34},{"date":159,"type":21},"2026-07",{"name":161,"class":162},"Bnai Zion Medical Center","OTHER_GOV",{"id":164,"slug":165,"hasResults":11,"nctId":166,"briefTitle":167,"officialTitle":168,"acronym":4,"eligibilityCriteria":169,"healthyVolunteers":11,"sex":16,"minAge":49,"maxAge":4,"enrollmentInfo":170,"targetDuration":4,"studyType":22,"phases":172,"briefSummary":173,"conditions":174,"keywords":175,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":179,"lastUpdatePostDateStruct":180,"startDateStruct":182,"completionDateStruct":184,"leadSponsor":185,"locationsCount":41},"100501974","phase-3-topical-treatment-for-tmj-arthralgia-100501974","NCT05816226","Topical Treatment for TMJ Arthralgia","Comparison of Topical 1% Diclofenac and Topical 2.5% Hydrocortisone for TMJ Arthralgia","Inclusion Criteria:\n\n* Arthralgia of at least 1 TMJ for at least 3 days\n\nExclusion Criteria:\n\n* Systemic pain condition\n* Past adverse reaction to steroid\n* Currently taking steroid\n* Taken steroid in the past \\_\\_\\_ months\n* Muscle relaxants (may start after study is complete)\n* New night guard during study, or within 1 month of start of study (may start after study is complete)",{"count":171,"type":21},90,[53],"The goal of this clinical trial is to evaluate the efficacy of topical 2.5% hydrocortisone in TMJ arthralgia. The main questions it aims to answer are:\n\n* How does pain reduction compare?\n* How does improvement in jaw function limitation compare?\n* How do side effects compare? Participants will\n* On day 1 be examined and report their pain level and jaw function limitation\n* On days 1-21, apply their cream four times a day\n* On day 21, report their pain level, jaw function limitation, compliance with instructions, and side effects.\n\nResearchers will compare topical 2.5% hydrocortisone and topical 1% diclofenac to see if efficacy and side effects differ.",[28],[176,177,27,178],"diclofenac","hydrocortisone","arthralgia","2024-12-05",{"date":181,"type":34},"2024-12-11",{"date":183,"type":34},"2023-06-01",{"date":71,"type":21},{"name":186,"class":76},"University of the Pacific"]